YNBY International Limited Stocks

HK$ 0.25Last Updated 27.04.2026

Issuer Rating

1/7
Performance

Poor

Risk

High

Recommendation

Sell

Market Cap

HK$ 247.88M

Buy
Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
HK$ 0.25
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Greatly overvalued vs peers

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

YNBY International Ltd., an investment holding company, engages in the money lending, and trading of goods and commodities in Hong Kong, the People's Republic of China, and internationally. The company operates through Money Lending; Trading of Goods and Commodities; and Cannabidiol (CBD) isolate segments. It provides short-term personal and corporate loans; and trades in refined edible oil, sugar, cosmetic, cannabidiol, and personal care products. Ban Loong Holdings Limited has a strategic cooperation agreement with Alpex Pharma SA to cooperate on the development and commercialization of nutraceutical products. The company was formerly known as ABC Communications (Holdings) Limited and changed its name to Ban Loong Holdings Limited in October 2015. Ban Loong Holdings Limited is based in Wan Chai, Hong Kong.

Company Valuation

Greatly overvalued
1/7

From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks. In particular, the stock is overpriced on P/E, 'expensive

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis
X-channel

Buy

Sell

0 more stocks